

BEACON

Biotech Ecosystem Advancement
through Collaboration and
Open Networking

10 September | Singapore



A Beacon for Biotech Innovation - Illuminating the Path from Breakthrough Science to Better Therapeutics

Singapore's biotech ecosystem is entering a **defining phase of growth**. With more than 70 biotech companies, over 60 biopharmaceutical manufacturing facilities, and 8 of the world's top 10 biopharma companies operating locally, the country is well positioned to translate scientific innovation into globally relevant therapeutics. Investments under RIE2030 are further accelerating progress across advanced biologics, AI-enabled discovery, and next-generation modalities.

BEACON (Biotech Ecosystem Advancement through Collaboration and Open Networking) **brings this growing community together**. The platform connects biotech innovators, biopharma leaders, researchers, and technology partners to exchange ideas, explore integrated approaches and build collaborations that can transform promising science into better drug candidates.

Join the **inaugural BEACON session** to gain fresh industry perspectives, connect with fellow innovators, and explore how emerging science, enabling technologies, and collaboration can accelerate the journey from discovery to therapeutic impact.

Learning Outcomes:

- Explore advances in antibody engineering for differentiated drug discovery.
- Discover emerging approaches in virus-inspired therapeutics and site-specific bioconjugation.
- Learn how integrated science and collaboration can accelerate the development of better drug candidates.

EVENT DETAILS:

Date

10 September 2026
Thursday

Time

11:00 – 14:00 hrs SGT

Venue

Nexus 1 Auditorium
Bridge+, Geneo 1A
Science Park Drive
Singapore, 119314

Reserve Your Seat

Please scan the QR code
or [click here](#) to register



BEACON

Biotech Ecosystem Advancement
through Collaboration and
Open Networking

10 September | Singapore



Program Agenda

Time (SGT)	Topic
10:30 hrs	<i>Registration and Meet and Greet</i>
11:00 hrs	Welcome and Opening Remarks
11:15 hrs	Drug Discovery Driven by Antibody Engineering Technologies Dr Zulkarnain Harfuddin Head, Partnering and Business Development - Chugai Pharmabody Research
11:30 hrs	Engineering Next-Generation Virus-Inspired Therapeutic Dr Kelly Wong Associate Director, Business Development - VerImmune
11:45 hrs	Singzyme PAL Technology: A Scalable Platform for Site-Specific, Safer Bioconjugates Dr Abbas Sahili CTO & Founding Team Leader - Singzyme
12:00 hrs	Panel Discussion - Beyond Discovery: Building Better Drug Candidates through Integrated Science
12:40 hrs	Agilent & You: Navigating the Ever-Changing Biopharma Landscape Together Terence Yap Biopharma Market Development Manager - Agilent Technologies
13:00 hrs	<i>Lunch and Networking</i>

DE-017096

This information is subject to change without notice.

©Agilent Technologies, Inc.
Published in the Singapore, August, 2026
BIO_26_BEACON_SG-01

